کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
9001532 1118528 2005 11 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer
موضوعات مرتبط
علوم پزشکی و سلامت داروسازی، سم شناسی و علوم دارویی داروشناسی
پیش نمایش صفحه اول مقاله
EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer
چکیده انگلیسی
Cetuximab inhibited growth of p53 wild-type HepG2 hepatocellular cancer cells in a time- and dose-dependent manner. Cetuximab treatment resulted in arresting the cell cycle in the G1/G0-phase due to an increase of expression of the cyclin-dependent kinase inhibitors p21Waf1/CIP1 and p27Kip1 and a decrease in cyclin D1 expression. Additionally, we observed a moderate increase in apoptosis as demonstrated by caspase-3 activation. Combining cetuximab with TKIs (erlotinib or AG1024) or the HMG-CoA-reductase inhibitor fluvastatin or doxorubicin resulted in synergistic antiproliferative effects. In contrast, p53 mutated Huh-7 hepatocellular cancer cells proved to be less sensitive towards cetuximab, but when combined with TKIs or fluvastatin or doxorubicin a pronounced reduction of cell growth was observed. To conclude, our study may provide a rationale for future clinical investigations of cetuximab combination therapy for growth control of hepatocellular cancer.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Biochemical Pharmacology - Volume 70, Issue 11, 25 November 2005, Pages 1568-1578
نویسندگان
, , , , ,